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Post-trial follow-up studies after randomized controlled trials (RCT) are increasingly
used to investigate the clinical effectiveness of an intervention in the long term.
“Legacy effect”, which was proposed in the context of such studies, describes the
effects of an intervention that are only observed after the end of trial and are not
due to the direct effects observed during the trial period itself. Much of the clinical
interest in legacy effects has been in the drug treatments for cardiovascular disease
prevention, as the finding of such effect could provide support for earlier initiation
of the intervention. However, limited attention has been paid to the methodological
challenges of analysing post-trial data.
In this thesis, I provide a summary of the methods used, and evaluate the potential
for bias, in the cardiovascular post-trial studies. I also investigate how we might best
analyze data from a matching RCT and post-trial follow-up study, specifically, the
choice of time period and trial participants to include in analysis and the strategy
to correct for potential selection bias and confounding. Simulations are conducted
to compare the performance of different methods. I use data from the Action to
Control Cardiovascular Risk in Diabetes (ACCORD) trial and its follow-up data to
illustrate the application of different approaches.
Analyses combining both the initial trial period and the post-trial follow-up period
have often been incorrectly interpreted as evidence of a legacy effect, which is better
assessed on the basis of separate post-trial analysis. To address the issues of selec-
tion bias and potential confounding requires appropriate study designs and rigorous
methods of analysis. The choice of statistical methods should consider the availabil-
ity of post-trial data, size of direct treatment effect and causal pathway of legacy
effect. It is recommended to conduct a sensitivity analysis to check the robustness
of the findings. Better reporting of legacy effects is needed to realize their full value
in informing clinical practice and health policy.
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